BU-NOT-SET
The rules of the game are changing for Contract Development and ManufacturingOrganizations (CDMOs). Once seen primarily as external service providers, CDMOs are now becoming innovation leaders who are helping shape the future of pharma.Supporting customers in navigating shifting industry demands, economic pressures, and the evolving therapeutic needs of patients, CDMOs play a key role in not just manufacturing, butmore innovative areas of the pharma sector.
Some of the key trends driving this change include:
- Demand for complex drug products:
Growth areas like Advanced Therapy Medicinal Products and injectable sterile biopharmaceuticals are reshaping the CDMO landscape. - Customer demand for true partnerships:
CDMOs are moving beyond transactional relationships, offering support from early analytical support, to tech transfer and full-scale manufacturing capabilities. - Supply chain resilience is crucial:
Recent disruptions have highlighted the need for more robust and reliable supply chain networks. CDMOs play a crucial role in supporting customers in delivering the critical products their patients rely on. - Innovation is key:
As customer markets expand due to ageing populations and growth of emerging markets, CDMOs are increasingly adopting technologies such as artificial intelligence to improve efficiency, regulatory compliance, and speed to market.
Read the full article in the September edition of CHEManager International, where Greg Behar, CEO of Recipharm gave his insights into these trends.
Learn more